tradmap

LNTH Lantheus Holdings, Inc.

$103.91 +0.67%

Healthcare · In Vitro & In Vivo Diagnostic Substances

Lantheus Holdings, Inc. (LNTH) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $6.8 billion. Shares last traded at $103.91, 3.7% below their 52-week high. Over the past year the stock is up 33.3%. LNTH trades at a price-to-earnings ratio of 28.97, below the In Vitro & In Vivo Diagnostic Substances median of 35.40. Net profit margin is 15.2%, above the peer median of -3.8%. Revenue grew 0.5% year over year.

Market Cap
$6.8B
Shares Out
65.1M
EPS (TTM)
$7.56
P/E Ratio
13.74
P/S Ratio
4.39
P/B Ratio
5.58
Dividend / Share
Dividend Yield
52-Week High
$107.89
52-Week Low
$47.25
Volume
47,151
Avg Vol (3m)
47,828.397

Performance

1W
-0.43%
1M
+11.90%
3M
+33.24%
6M
+59.51%
YTD
+54.44%
1Y
+33.29%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
64.77
SMA (50)
$92.65
SMA (200)
$70.86
Price vs SMA50
+12.16%
Price vs SMA200
+46.64%
ATR (14)
$3.54

Financials

Revenue
$1.5B
Net Income
$234M
Gross Margin
61.1%
Operating Margin
20.2%
Net Margin
15.2%
Return on Equity
19.3%
Return on Assets
10.0%
Current Ratio
2.83
Debt / Equity
0.46
Revenue Growth (YoY)
+0.5%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $1.80 2026-05-07
FY 2025 $3.41 2026-02-26
Q3 2025 $2.60 2025-11-06
Q2 2025 $2.14 2025-08-06
Q1 2026 $1.02 2026-05-07
FY 2025 $4.36 2026-02-26

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

LNTH vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap.

P/E vs peers
28.97 / 35.40 med
-18% discount
P/S vs peers
4.39 / 4.39 med
+0% premium
Net margin vs peers
15.2% / -3.8% med
above median
1–14 of 14
IDXXIdexx Laboratories$44.3B41.8410.3024.6%+2.91%
LNTHLantheus Holdings, Inc.$6.8B28.974.3915.2%+0.67%
CLDXCelldex Therapeutics, Inc.$2.5B-9.84-1.47%
NTLAIntellia Therapeutics, Inc.$2.2B-5.30+2.25%
NEOGNeogen Corp$2.0B-1.85+4.14%
QDELQuidelortho Corp$932M+4.27%
ACHVAchieve Life Sciences, Inc.$496M-9.07-9.72%
MYGNMyriad Genetics Inc$429M-1.170.52-44.4%+3.65%
TKNOAlpha Teknova, Inc.$282M-16.326.95-42.6%+6.38%
IMDXInsight Molecular Diagnostics Inc.$176M-3510.5043.48-1.2%+2.25%
ICCCIMMUCELL CORP /DE/$86M-82.253.09-3.8%+0.53%
QCLSQ/C TECHNOLOGIES, INC.$32M-2.72+4.28%
VNRXVOLITIONRX LTD$12M-0.52+6.14%
CDIOCardio Diagnostics Holdings, Inc.$6M+2.53%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.